Journal of Clinical Infectious Diseases & Practice
Open Access

Functional nucleic acids; Infectious diseases; Detection, Prevention; Aptamers; DNAEzymes; RNA interference; Diagnostics; Therapeutics

Introduction

Infectious diseases remain a significant global health challenge, necessitating innovative approaches for effective detection and prevention. Traditional diagnostic methods often lack the sensitivity and speed required for timely intervention, leading to increased morbidity and mortality. Functional nucleic acids, such as aptamers and DNAzymes, have emerged as promising alternatives due to their unique properties, including high specificity, stability, and ease of synthesis [1]. Aptamers, which are short, single-stranded oligonucleotides, can selectively bind to target pathogens or their biomarkers, facilitating rapid identification. DNAzymes, or catalytic DNA, exhibit enzymatic activity and can be designed to cleave specific RNA targets, providing a mechanism for pathogen control. Moreover, RNA interference (RNAi) technologies offer targeted gene silencing, effectively mitigating the effects of viral infections and resistant bacteria.

Methodology

Literature review: Objective: Gather existing knowledge on functional nucleic acids used in infectious disease diagnostics and therapeutics. Systematically review recent publications, focusing on the design, applications, and efficacy of aptamers, DNAzymes, and RNA interference in various pathogens [2-5].

Selection of target pathogens: Identify specific pathogens of interest for study. Choose a range of infectious agents, including bacteria (e.g., Escherichia coli), viruses (e.g., Influenza virus), and fungi (e.g., Candida albinos), based on prevalence and impact on public health.

Design of functional nucleic acids: Develop aptamers, DNAzymes, and RNAi constructs targeting specific pathogen markers. Aptamers development use SELEX (Systematic Evolution of Ligands by Exponential Enrichment) to select aptamers that bind to pathogen-specific targets. Design DNAzymes with specific catalytic activity against target RNA sequences of pathogens [6]. RNAi designs synthesize small interfering RNA (siRNA) or short hairpin RNA (shRNA) targeting viral genes or essential bacterial genes.

In vitro testing: Evaluate the specificity and sensitivity of functional nucleic acids. Binding assays perform surface Plasmon resonance (SPR) or enzyme-linked oligonucleotide assays (ELONA) to measure aptamers binding affinity. Activity assays assess the catalytic activity of DNAzymes using fluorescence or colorimetric methods [7]. Silencing efficacy conduct qPCR and Western blot analysis to determine the effectiveness of RNAi constructs in reducing target gene expression.

In vivo studies: Test the therapeutic potential and safety of selected functional nucleic acids. Animal Models: Use appropriate animal models (e.g., mice) to evaluate the efficacy of aptamers, DNAzymes, or RNAi in controlling infections. Administration routes explore various delivery methods (e.g., intravenous, oral, aerosol) to optimize bioavailability [8,9]. Monitoring outcomes assess clinical parameters, pathogen load, and immune responses through blood tests and tissue analysis.

Data analysis: Ensure reliability and validity of results. Action use statistical software to analyze data from binding assays, in vitro tests, and in vivo studies, applying methods such as ANOVA or t-tests to compare treatment groups.

Ethical considerations: Adhere to ethical standards in research. Action obtains necessary approvals for animal studies and ensures humane treatment throughout experiments. Share research outcomes with the scientific community [10]. Action prepare manuscripts for peer-reviewed journals, presentations at conferences, and engage in collaborations to expand the impact of findings.

Conclusion

The integration of innovative functional nucleic acids into the landscape of infectious disease detection and prevention holds significant promise for enhancing global health outcomes. Through their high specificity, sensitivity, and versatility, aptamers, DNAEzymes, and RNA interference technologies offer revolutionary approaches for timely diagnosis and targeted therapeutic interventions. This methodology underscores the potential of these nucleic acids to address the challenges posed by infectious diseases, including rapid identification of pathogens and effective control strategies against resistant strains. As research continues to advance in this field, further exploration of these tools will not only improve our understanding of microbial interactions but also pave the way for more effective public health measures. Overall, the continued development and application of functional nucleic acids can lead to transformative solutions in infectious disease management, ultimately contributing to better prevention strategies and improved patient outcomes.

Acknowledgement

None

Conflict of Interest

None

References

1. Theo V (2016)Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990-2015: a systematic analysis for the Global Burden of Disease Study 2015.Lancet 388: 1545-1602.
2. Gallego O (2015)Nonsurgical treatment of recurrent glioblastoma.Current Oncology 22: 273-281.
3. Hart MG, Garside R, Rogers G, Stein K, Grant R, et al. (2013) Temozolomide for high grade glioma. The Cochrane Database of Systematic Reviews 4: 007415.
4. Bleeker FE, Molenaar RJ, Leenstra S (2012)Recent advances in the molecular understanding of glioblastoma.Journal of Neuro-Oncology 108: 11-27.
5. Khosla D (2016) Concurrent therapy to enhance radiotherapeutic outcomes in glioblastoma. Annals of Translational Medicine 4: 54.
6. Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, et al. (2010)Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. Cancer Journal for Clinicians 60: 166-193.
7. Stupp Roger, Hegi Monika E, Mason Warren P, Bent Martin J van den, Taphoorn Martin JB, et al. (2009)Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.The Lancet Oncology 10: 459-466.
8. McNeill KA (2016) Epidemiology of Brain Tumors.Neurologic Clinics34: 981-998.
9. Alifieris C, Trafalis DT (2015)Glioblastoma multiforme: Pathogenesis and treatment.Pharmacology & Therapeutics 152: 63-82.
10. Suryawanshi YR, Schulze AJ (2021)Oncolytic Viruses for Malignant Glioma: On the Verge of Success?Viruses 13: 1294.